NCT06606106Active, not recruitingPhase 1
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
A Multiple-Ascending Dose Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of LY3537031 in Overweight and Obese Participants and Healthy Volunteers
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
This is a 4-part study that includes a Part A, Part B, Part C, and Part D. Parts A and D will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants. Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body weight will be measured. The study will last approximately 49 weeks excluding a screening period.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 302 (estimated)
- First submitted
- 27 Aug 2024
- Start date
- 5 Sept 2024
- Primary completion date
- Nov 2026
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Obesity
- NCT number
- NCT06606106
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 302
- From 5 Sept 2024 to the primary completion date, Nov 2026
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have undergone any form of bariatric surgery
- Have taken medications that promote weight loss within 90 days before screening
Lab values
- Have a serum calcitonin level (at screening) of greater than or equal to 35 nanograms per liter (ng/L) (35 picograms per milliliter (pg/mL), 10.2 picomoles per liter (pmol/L))
Other
- Participants who are lactating
Who the study is looking for
- Have a BMI within the range of:
- Parts A and D: 27.0 to 45.0 kilogram per square meter (kg/m²)
- Parts B and C: 22.0 to 26.9 kg/m²
- Parts B and C: Weigh 60 kg (80 pounds (lbs)) or more at screening
- Have no significant (not more than 5%) self-reported weight gain or loss in the past 3 months prior to screening
- Have a thyroid stimulating hormone (TSH) value within normal local laboratory ranges.
Age in the registry: 22 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fortrea Clinical Research Unit Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
| Fortrea Clinical Research Unit Coordinator of this site? Confirm its status | Daytona Beach | United States | Unknown status |
| Collaborative Neuroscience Research, LLC Coordinator of this site? Confirm its status | Los Alamitos | United States | Unknown status |
| Clinical Pharmacology of Miami Coordinator of this site? Confirm its status | Miami | United States | Unknown status |
| QPS Coordinator of this site? Confirm its status | Springfield | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.